Description General description A cell-permeable analog of HNMPA that yields the parent compound upon cleavage by cytosolic esterases. Inhibits insulin receptor tyrosine kinase (IC50 = 100 µM) and insulin-stimulated glucose oxidation in isolated rat adipocytes (IC50 = 10 µM). Also reported to inhibit tyrosine autophosphorylation of the human insulin receptor (IC50 = 200 µM). A cell-permeable analog of HNMPA. Inhibits insulin receptor tyrosine kinase (IC50 = 100 mM) and insulin-stimulated glucose oxidation in isolated rat adipocytes (IC50 = 10 µM). Also reported to inhibit tyrosine autophosphorylation of the human insulin receptor (IC50 = 200 µM). It has no effect on PKA (at concentrations up to 1 mM) or PKC (at concentrations up to 420 µM). Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target tyrosine kinase Product does not compete with ATP. Reversible: no Target IC50: 100 µM and 10 µM against insulin receptor tyrosine kinase and insulin-stimulated glucose oxidation in isolated rat adipocytes, respectively Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Baltensperger, K., et al. 1992. Proc. Natl. Acad. Sci. USA89, 7885. Saperstein, R., et al. 1989. Biochemistry28, 5694.